According to Sri Lankan study funded by World Health Organization (WHO), British High Commission (Colombo) and Chinese Academy of Science, the efficacy of the single dose of Covishield vaccine declined after 16 weeks in people above the age of 60 years.
However, Professor Neelika Malavige from the Department of Immunology and Molecular Science, Sri Jayawardenepura University, informed on microblogging site Twitter that those aged below 60 years had “very good responses” and 93 per cent of them had developed antibodies at 16 weeks after a single dose.
Our paper on the first dose responses of Covishield vaccine is published in @NatureComms. 93.4% individuals developed antibodies to a single dose of the vaccine and 97.1% developed neutralizing antibodies. https://t.co/YZejTpCVBo
— Neelika Malavige (@GMalavige) July 29, 2021
The study observed that although WHO and policy makers’ had recommended those previously infected with the virus to receive the vaccine, many people have continued to remain hesitant.
Sri Lanka is yet to vaccinate more than 5 lakh individuals with the second dose of Covishield vaccine. The government had placed an order of 10 million doses of Serum Institute of India-manufactured Covishield at a cost of $52.5 million along with 3.5 million doses from AstraZeneca Institute of United Kingdom under the COVAX programme.
According to Global Times, the country received the largest COVID-19 vaccine donation from China on July 27. The East Asian country also donated syringes to the Health Ministry of Sri Lanka.
Over six million citizens of Sri Lanka are inoculated with China’s Sinopharm vaccine.